Table of Content

1. PREFACE
1.1. Antibody Drug Conjugate Market Overview
1.2. Key Market Insights
1.3. Scope of the Report
1.4. Research Methodology
1.5. Key Questions Answered
1.6. Chapter Outlines

2. EXECUTIVE SUMMARY

3. INTRODUCTION
3.1. Chapter Overview
3.2. Pillars of Cancer Therapy
3.3. Overview of Antibody Drug Conjugates
3.3.1. History of Antibody Drug Conjugates
3.3.2. Difference between Small Molecule Drugs, Monoclonal Antibody Therapies and Antibody Drug Conjugates
3.3.3. Components of Antibody Drug Conjugates
3.3.3.1. Antibody
3.3.3.2. Cytotoxin
3.3.3.3. Linker
3.3.4. Advantages of Antibody Drug Conjugates Therapeutics over Traditional Therapeutics
3.3.5. Pharmacokinetic Properties of Antibody-Drug Conjugates
3.3.5.1. Absorption
3.3.5.2. Distribution
3.3.5.3. Metabolism and Elimination
3.4. Concluding Remarks

4. MARKET OVERVIEW
4.1. Chapter Overview
4.2. Antibody Drug Conjugates: Therapies Pipeline
4.2.1. Analysis by Status of Development
4.2.2. Analysis by Target Disease Indication
4.2.3. Analysis by Therapeutic Area
4.2.4. Analysis by Line of Treatment
4.2.5. Analysis by Dosing Frequency
4.2.6. Analysis by Type of Therapy
4.2.7. Analysis by Target Antigen
4.2.8. Analysis by Antibody Isotype
4.2.9. Analysis by Payload / Cytotoxin / Warhead
4.2.10. Analysis by Type of Payload
4.2.11. Analysis by Linker
4.2.12. Analysis by Type of Linker (Cleavable / Non-Cleavable)
4.3. Antibody Drug Conjugate: List of Therapy Developers
4.3.1. Analysis by Year of Establishment
4.3.2. Analysis by Company Size
4.3.3. Analysis by Location of Headquarters
4.3.4. Analysis by Company size and Location of Headquarters
4.3.5. Most Active Players: Analysis by Number of Therapies

5. TARGET COMPETITIVENESS ANALYSIS
5.1. Chapter Overview
5.2. Key Parameters
5.3. Methodology
5.4. Target Competitiveness Analysis: Key Targets of Antibody Drug Conjugates
5.4.1. Three-Dimensional Bubble Analysis
5.4.1.1. Targets of Approved / Marketed Drugs
5.4.1.2. Targets of Phase III Drugs
5.4.1.3. Targets of Phase II Drugs
5.4.1.4. Targets of Phase I Drugs
5.4.1.5. Targets of Pre-Clinical Drugs
5.4.2. Six-Dimensional Spider Web Analysis

6. COMPANY AND DRUG PROFILES
6.1. Chapter Overview
6.2. ADC Therapeutics
6.2.1. Company Overview
6.2.2. Financial Information
6.2.3. Pipeline Overview
6.2.3.1. Zynlonta
6.2.4. Recent Developments and Future Outlook
6.3. Astellas Pharma
6.3.1. Company Overview
6.3.2. Financial Information
6.3.3. Pipeline Overview
6.3.3.1. Padcev
6.3.4. Recent Developments and Future Outlook
6.4. AstraZeneca
6.4.1. Company Overview
6.4.2. Financial Information
6.4.3. Pipeline Overview
6.4.3.1. Enhertu
6.4.4. Recent Developments and Future Outlook
6.5. Byondis
6.5.1. Company Overview
6.5.2. Financial Information
6.5.2.1. Pipeline Overview
6.5.3. Trastuzumab duocarmazine
6.5.4. Recent Developments and Future Outlook
6.6. Daiichi Sankyo
6.6.1. Company Overview
6.6.2. Financial Information
6.6.3. Pipeline Overview
6.6.3.1. Enhertu
6.6.4. Recent Developments and Future Outlook
6.7. Genentech (Subsidiary of Roche)
6.7.1. Company Overview
6.7.2. Financial Information
6.7.3. Pipeline Overview
6.7.3.1. Kadcyla
6.7.3.2. Polivy
6.7.4. Recent Developments and Future Outlook
6.8. Gilead Sciences
6.8.1. Company Overview
6.8.2. Financial Information
6.8.3. Pipeline Overview
6.8.3.1. Trodelvy
6.8.4. Recent Developments and Future Outlook
6.9. ImmunoGen
6.9.1. Company Overview
6.9.2. Financial Information
6.9.3. Pipeline Overview
6.9.3.1. Elahere
6.9.4. Recent Developments and Future Outlook
6.10. Pfizer
6.10.1. Company Overview
6.10.2. Financial Information
6.10.3. Pipeline Overview
6.10.3.1. Mylotarg
6.10.3.2. Besponsa
6.10.4. Recent Developments and Future Outlook
6.11. RemeGen
6.11.1. Company Overview
6.11.2. Financial Information
6.11.3. Pipeline Overview
6.11.3.1. Disitamab vedotin
6.11.4. Recent Developments and Future Outlook
6.12. Seagen
6.12.1. Company Overview
6.12.2. Financial Information
6.12.3. Pipeline Overview
6.12.3.1. Adcetris
6.12.3.2. Padcev
6.12.3.3. Tivdak
6.12.4. Recent Developments and Future Outlook

7. CLINICAL TRIAL ANALYSIS
7.1. Chapter Overview
7.2. Scope and Methodology
7.3. Antibody Drug Conjugates: Clinical Trial Analysis
7.3.1. Analysis by Trial Registration Year
7.3.2. Analysis by Trial Status
7.3.3. Analysis by Trial Status and Patients Enrolled
7.3.4. Analysis by Trial Registration Year and Trial Status
7.3.5. Analysis by Trial Registration Year and Patients Enrolled
7.3.6. Analysis by Trial Phase
7.3.7. Analysis by Trial Phase and Patients Enrolled
7.3.8. Analysis by Type of Sponsor / Collaborator
7.3.9. Analysis by Target Population
7.3.10. Analysis by Study Design
7.3.11. Most Active Industry Players: Analysis by Number of Trials
7.3.12. Most Active Non-Industry Players: Analysis by Number of Trials
7.3.13. Analysis of Clinical Trials by Geography
7.3.14. Analysis of Patients Enrolled by Geography

8. KEY OPINION LEADERS
8.1. Chapter Overview
8.2. Assumption and Key Parameters
8.3. Methodology
8.4. Antibody Drug Conjugates: Key Opinion Leaders
8.4.1. Analysis by Type of KOLs
8.4.2. Analysis by Qualification
8.4.3. Analysis by Affiliated Organization
8.4.4. Analysis by Type of Organization
8.4.5. Analysis by Geographical Location of KOLs
8.4.6. Most Prominent KOLs: Analysis by KOLs Activeness, Expertise and Strength
8.4.7. Most Prominent KOLs: Analysis by RA score
8.4.8. Most Prominent KOLs: Comparison of RA Score and Third-Party Score

9. COMBINATION THERAPIES
9.1. Chapter Overview
9.2. Combination Therapies: History of Development
9.3. Combination Therapies: FDA Guidelines
9.3.1. Combination of Marketed Drugs
9.3.2. Combinations of Marketed Drugs with New Molecular Entities
9.3.3. Combination of New Molecular Entities
9.4. Combination Therapies: Antibody Drug Conjugates
9.4.1. Completed / Ongoing Clinical Studies of Antibody Drug Conjugates
9.4.1.1. Analysis by Type of Therapy
9.4.2. Completed / Ongoing Clinical Studies of Antibody Drug Conjugate-based Combination Therapies
9.4.2.1. Analysis by Phase of Development
9.4.2.2. Analysis by Trial Status
9.4.2.3. Analysis by Target Disease Indication
9.4.2.4. Most Popular Antibody Drug Conjugates Used in Combination Therapies: Analysis by Number of Trials
9.4.2.5. Most Popular Drug Class Used in Combination Therapies: Analysis by Number of Trials
9.4.2.6. Analysis by Target Disease Indication and Drug Class Used in Antibody Drug Conjugate-based Combination Therapies
10. PARTNERSHIPS AND COLLABORATIONS
10.1. Chapter Overview
10.2. Partnership Models
10.3. Antibody Drug Conjugates: List of Partnerships and Collaborations
10.3.1. Analysis by Year of Partnership
10.3.2. Analysis by Type of Partnership
10.3.3. Analysis by Year and Type of Partnership
10.3.4. Analysis by Purpose of Partnership
10.3.5. Analysis by Type of Partner
10.3.6. Most Active Players: Analysis by Number of Partnerships
10.3.7. Analysis by Geography
10.3.7.1. International and Local Agreements
10.3.7.2. Intercontinental and Intracontinental Agreements
11. FUNDING AND INVESTMENT ANALYSIS
11.1. Chapter Overview
11.2. Types of Funding
11.3. Antibody Drug Conjugates: List of Funding and Investment Analysis
11.3.1. Analysis by Year of Funding
11.3.2. Analysis by Amount Invested
11.3.3. Analysis by Type of Funding
11.3.4. Analysis by Year and Type of Funding
11.3.5. Analysis by Type of Investor
11.3.6. Analysis by Amount Invested by Geography
11.3.6.1. Analysis by Region
11.3.6.2. Analysis by Country
11.3.7. Most Active Players: Analysis by Number of Funding Instances
11.3.8. Most Active Players: Analysis by Amount Invested
11.3.9. Key Investors: Analysis by Number of Funding Instances
12. PATENT ANALYSIS
12.1. Chapter Overview
12.2. Scope and Methodology
12.3. Antibody Drug Conjugates: Patent Analysis
12.3.1. Analysis by Patent Publication Year
12.3.2. Analysis by Patent Application Year
12.3.3. Analysis by Annual Number of Granted Patents and Patent Applications
12.3.4. Analysis by Patent Jurisdiction
12.3.5. Analysis by CPC Symbols
12.3.6. Analysis by Type of Applicant
12.3.7. Leading Industry Players: Analysis by Number of Patents
12.3.8. Leading Non-Industry Players: Analysis by Number of Patents
12.3.9. Leading Individual Assignees: Analysis by Number of Patents
12.4. Antibody Drug Conjugate: Patent Benchmarking Analysis
12.4.1. Analysis by Patent Characteristics
12.5. Antibody Drug Conjugate: Patent Valuation
12.6. Leading Patents by Number of Citations

13. ACADEMIC GRANTS ANALYSIS
13.1. Chapter Overview
13.2. Scope and Methodology
13.3. Antibody Drug Conjugates: Grants Analysis
13.3.1. Analysis by Year of Grant Award
13.3.2. Analysis by Amount Awarded
13.3.3. Analysis by Funding Institute
13.3.4. Analysis by Support Period
13.3.5. Analysis by Type of Grant Application
13.3.6. Analysis by Purpose of Grant Award
13.3.7. Analysis by Activity Code
13.3.8. Analysis by Study Section Involved
13.3.9. Popular NIH Departments: Analysis by Number of Grants
13.3.9.1. Prominent Program Officers: Analysis by Number of Grants
13.3.9.2. Popular Recipient Organizations: Analysis by Number of Grants
13.3.9.3. Popular Recipient Organizations: Analysis by Grant Amount
13.3.10. Analysis by Region of Recipient Organization

14. KEY COMMMERCIALIZATION STRATEGIES
14.1. Chapter Overview
14.2. Successful Drug Launch Strategy: ROOTS Framework
14.3. Successful Drug Launch Strategy: Product Differentiation
14.4. Common Commercialization Strategies Adopted Across Different Stages of Product Development
14.5. Key Commercialization Strategies Adopted by the Companies Focused on Antibody Drug Conjugates
14.5.1. Participation in the Global Events
14.5.2. Collaboration with External Stakeholders and Pharmaceuticals Firms
14.5.3. Geographical Expansion
14.5.4. Awareness Through Product Website
14.6. Concluding Remarks

15. PROMOTIONAL ANALYSIS
15.1. Chapter Overview
15.2. Channels Used for Promotional Campaigns
15.3. Summary of Product Website
15.4. Summary of Patient Support Services and Informative Downloads
15.5. Adcetris: Promotional Analysis
15.5.1. Drug Overview
15.5.2. Product Website Analysis
15.5.2.1. Message for Healthcare Professional
15.5.2.2. Message for Patients
15.5.2.3. Informative Downloads
15.5.2.4. Patient Support Services
15.6. Besponsa: Promotional Analysis
15.6.1. Drug Overview
15.6.2. Product Website Analysis
15.6.2.1. Message for Healthcare Professional
15.6.2.2. Message for Patients
15.6.2.3. Informative Downloads
15.6.2.4. Patient Support Services
15.7. Enhertu: Promotional Analysis
15.7.1. Drug Overview
15.7.2. Product Website Analysis
15.7.2.1. Message for Healthcare Professional
15.7.2.2. Message for Patients
15.7.2.3. Informative Downloads
15.7.2.4. Patient Support Services
15.8. Kadcyla: Promotional Analysis
15.8.1. Drug Overview
15.8.2. Product Website Analysis
15.8.2.1. Message for Healthcare Professional
15.8.2.2. Message for patients
15.8.2.3. Informative Downloads
15.8.2.4. Patient Support Services
15.9. Mylotarg: Promotional Analysis
15.9.1. Drug Overview
15.9.2. Product Website Analysis
15.9.2.1. Message for Healthcare Professional
15.9.2.2. Message for patients
15.9.2.3. Informative Downloads
15.9.2.4. Patient Support Services
15.10. Polivy: Promotional Analysis
15.10.1. Drug Overview
15.10.2. Product Website Analysis
15.10.2.1. Message for Healthcare Professional
15.10.2.2. Message for Patients
15.10.2.3. Informative Downloads
15.10.2.4. Patient Support Services
15.11. Trodelvy: Promotional Analysis
15.11.1. Drug Overview
15.11.2. Product Website Analysis
15.11.2.1. Message for Healthcare Professional
15.11.2.2. Message for Patients
15.11.2.3. Informative Downloads
15.11.2.4. Patient Support Services

16. SUCCESS PROTOCOL ANALYSIS
16.1. Chapter Overview
16.2. Antibody Drug Conjugates: Success Protocol Analysis
16.3. Adcetris (Seagen / Takeda Oncology)
16.3.1. Overview
16.3.2. Approval Timeline
16.3.3. Success Protocol Analysis
16.4. Aidixi (RemeGen)
16.4.1. Overview
16.4.2. Approval Timeline
16.4.3. Success Protocol Analysis
16.5. Akalux (Rakuten Medical)
16.5.1. Overview
16.5.2. Approval Timeline
16.5.3. Success Protocol Analysis
16.6. Besponsa (Pfizer / UCB)
16.6.1. Overview
16.6.2. Approval Timeline
16.6.3. Success Protocol Analysis
16.7. Blenrep (GlaxoSmithKline)
16.7.1. Overview
16.7.2. Approval Timeline
16.7.3. Success Protocol Analysis
16.8. Elahere (ImmunoGen)
16.8.1. Overview
16.8.2. Approval Timeline
16.8.3. Success Protocol Analysis
16.9. Enhertu (Daiichi Sankyo / AstraZeneca)
16.9.1. Overview
16.9.2. Approval Timeline
16.9.3. Success Protocol Analysis
16.10. Kadcyla (Genentech / ImmunoGen)
16.10.1. Overview
16.10.2. Approval Timeline
16.10.3. Success Protocol Analysis
16.11. Padcev (Seagen / Astellas Pharma)
16.11.1. Overview
16.11.2. Approval Timeline
16.11.3. Success Protocol Analysis
16.12. Polivy (Genentech)
16.12.1. Overview
16.12.2. Approval Timeline
16.12.3. Success Protocol Analysis
16.13. Tivdak (Seagen / Genmab)
16.13.1. Overview
16.13.2. Approval Timeline
16.13.3. Success Protocol Analysis
16.14. Trodelvy (Gilead Sciences)
16.14.1. Overview
16.14.2. Approval Timeline
16.14.3. Success Protocol Analysis
16.15. Zynlonta (ADC Therapeutics)
16.15.1. Overview
16.15.2. Approval Timeline
16.15.3. Success Protocol Analysis
16.16. Concluding Remarks

17. NOVEL CONJUGATION AND LINKER TECHNOLOGY PLATFORMS
17.1. Chapter Overview
17.2. Antibody Drug Conjugates: Conjugation Technologies
17.2.1. Chemical Conjugation
17.2.2. Enzymatic Conjugation
17.3. Antibody Drug Conjugates: List of Conjugation Technologies
17.4. Antibody Drug Conjugates: Linker Technologies
17.4.1. Non-cleavable Linkers
17.4.2. Cleavable Linker
17.5. Antibody Drug Conjugates: List of Linker and Linker-Payload Technologies
17.6. Concluding Remarks

18. ASSESSMENT OF NON-CLINICAL DATA FIRST IN HUMAN DOSING
18.1. Chapter Overview
18.2. Antibody Drug Conjugates: Non-Clinical Studies
18.3. ICH S9 Guidelines
18.4. Investigational New Drug (IND)-Enabling Study Designs
18.4.1. Example Case: Kadcyla
18.5. Toxicities in Animal Models
18.6. Prediction of Maximum Tolerated Dosage (MTD) in Humans
18.7. Other Key Considerations for Study Design

19. COST PRICE ANALYSIS
19.1. Chapter Overview
19.2. Factors Contributing Towards the High Price of Antibody-Drug Conjugates
19.3. Antibody Drug Conjugates Market: Cost Price Analysis
19.3.1. On the Basis of Associated Costs
19.3.2. On the Basis of Competition
19.3.3. On the Basis of Patient Segment
19.4. Reimbursement Considerations for Antibody-Drug Conjugates
20. CASE STUDY 1: CONTRACT MANUFACTURING OF ANTIBODY-DRUG CONJUGATES
20.1. Chapter Overview
20.2. Key Steps in Antibody Drug Conjugate Manufacturing Process
20.3. Technical Challenges Related to Antibody Drug Conjugate Manufacturing
20.4. Challenges Associated with Supply Chain and Method Transfer
20.5. Limitations of In-House Manufacturing
20.6. Investments in Antibody Drug Conjugate Manufacturing Capability Expansions
20.7. Collaborations Established for Antibody-Drug Conjugate Manufacturing
20.8. Growing Demand for Antibody-Drug Conjugate Contract Manufacturing
20.9. CMOs with Linker Manufacturing Capabilities
20.10. CMOs with HPAPI / Cytotoxic Payload Manufacturing Capabilities
20.11. CMOs with Conjugation Capabilities
20.12. Antibody Drug Conjugate One-Stop-Shops
20.13. Increasing Demand for One-Stop-Shops
21. CASE STUDY 2: COMPANION DIAGNOSTICS FOR ANTIBODY DRUG CONJUGATES THERAPEUTICS
21.1. Chapter Overview
21.1.1. Advantages of Companion Diagnostics
21.1.2. Challenges Associated with the Development of Companion Diagnostics
21.2. Companion Diagnostics for Antibody Drug Conjugates
21.3. Companion Diagnostics For Antibody Therapeutics
21.3.1. Analysis by Target Antigen
21.3.2. Analysis by Type of Cancer
21.4. Most Prominent Players: Analysis by Number of Tests
22. SWOT ANALYSIS
22.1. Chapter Overview
22.2. Strengths
22.2.1. Improved Safety and Patient Adherence
22.2.2. Rise of Next-Generation Conjugation Technologies
22.2.3. Robust Pipeline with Multiple Late Stage Product Candidates
22.2.4. Growing Involvement of Academic Institutes
22.3. Weaknesses
22.3.1. Technical Complexities Associated with Product Development
22.3.2. Manufacturing, Logistics and Supply Chain Challenges
22.3.3. Batch to Batch Inconsistencies
22.4. Opportunities
22.4.1. Increasing Collaborations and VC Funding
22.4.2. Widening Therapeutics Reach
22.4.3. Life Cycle Management
22.4.4. Combination Therapies
22.4.5. Opportunities for CMOs
22.5. Threats
22.5.1. Failure of Clinical / Marketed Candidates
22.5.2. Increased Competition from Other Therapeutic Classes
23. MARKET FORECAST AND OPPORTUNITY ANALYSIS
23.1. Chapter Overview
23.2. Forecast Methodology and Key Assumptions
23.3. Global Antibody Drug Conjugates Market, 2023-2035
23.3.1. Global Antibody Drug Conjugates Market: Distribution by Target Disease Indication, 2023 and 2035
23.3.1.1. Antibody Drug Conjugates Market for Breast Cancer, 2023-2035
23.3.1.2. Antibody Drug Conjugates Market for B-cell Lymphoma, 2023-2035
23.3.1.3. Antibody Drug Conjugates Market for Lung Cancer, 2023-2035
23.3.1.4. Antibody Drug Conjugates Market for Multiple Myeloma, 2023-2035
23.3.1.5. Antibody Drug Conjugates Market for Renal Cancer, 2023-2035
23.3.1.6. Antibody Drug Conjugates Market for Gastric Cancer, 2023-2035
23.3.1.7. Antibody Drug Conjugates Market for Cervical Cancer, 2023-2035
23.3.1.8. Antibody Drug Conjugates Market for Acute Lymphoblastic Leukemia, 2023-2035
23.3.1.9. Antibody Drug Conjugates Market for Other Disease Indications, 2023-2035
23.3.2. Antibody Drug Conjugates Market: Distribution by Therapeutic Area, 2023 and 2035
23.3.2.1. Antibody Drug Conjugates Market for Solid Tumors, 2023-2035
23.3.2.2. Antibody Drug Conjugates Market for Hematological Cancer, 2023-2035
23.3.3. Global Antibody Drug Conjugates Market: Distribution by Linker, 2023 and 2035
23.3.3.1. Antibody Drug Conjugates Market for Valine-Citrulline Linker, 2023-2035
23.3.3.2. Antibody Drug Conjugates Market for Tetrapeptide-Based Linker, 2023-2035
23.3.3.3. Antibody Drug Conjugates Market for Succinimidyl-4-(N-maleimidomethyl) cyclohexane-1-carboxylate Linker, 2023-2035
23.3.3.4. Antibody Drug Conjugates Market for Maleimide Linker, 2023-2035
23.3.3.5. Antibody Drug Conjugates Market for Maleimidocaproyl Linker, 2023-2035
23.3.3.6. Antibody Drug Conjugates Market for Valine-Alanine Linker, 2023-2035
23.3.3.7. Antibody Drug Conjugates Market for Hydrazone (4-(4-acetylphenoxy) butanoic acid (AcBut) Linker, 2023-2035
23.3.3.8. Antibody Drug Conjugates Market for Other Linkers, 2023-2035
23.3.4. Antibody Drug Conjugates Market: Distribution by Type of Payload, 2023 and 2035
23.3.4.1. Antibody Drug Conjugates Market for Monomethyl Auristatin E Payloads, 2023-2035
23.3.4.2. Antibody Drug Conjugates Market for DM1 Payloads, 2023-2035
23.3.4.3. Antibody Drug Conjugates Market for SN-38 / Irinotecan Payloads, 2023-2035
23.3.4.4. Antibody Drug Conjugates Market for Monomethyl Auristatin F Payloads, 2023-2035
23.3.4.5. Antibody Drug Conjugates Market for Duocarmycin Payloads, 2023-2035
23.3.4.6. Antibody Drug Conjugates Market for SG3199 Payloads, 2023-2035
23.3.4.7. Antibody Drug Conjugates Market for Ozogamicin Payloads, 2023-2035
23.3.4.8. Antibody Drug Conjugates Market for DM4 Payloads, 2023-2035
23.3.4.9. Antibody Drug Conjugates Market for Other Payloads, 2023-2035
23.3.5. Global Antibody Drug Conjugates Market: Distribution by Target Antigen, 2023 and 2035
23.3.5.1. Antibody Drug Conjugates Market for HER-2 (ERBB2), 2023-2035
23.3.5.2. Antibody Drug Conjugates Market for CD79b, 2023-2035
23.3.5.3. Antibody Drug Conjugates Market for TROP-2, 2023-2035
23.3.5.4. Antibody Drug Conjugates Market for BCMA (TNFRSF17 / BCM), 2023-2035
23.3.5.5. Antibody Drug Conjugates Market for CD19, 2023-2035
23.3.5.6. Antibody Drug Conjugates Market for Nectin 4, 2023-2035
23.3.5.7. Antibody Drug Conjugates Market for Tissue Factor, 2023-2035
23.3.5.8. Antibody Drug Conjugates Market for CD22, 2023-2035
23.3.5.9. Antibody Drug Conjugates Market for CD30, 2023-2035
23.3.5.10. Antibody Drug Conjugates Market for CEACAM5, 2023-2035
23.3.5.11. Antibody Drug Conjugates Market for Other Target Antigens, 2023-2035
23.3.6. Antibody Drug Conjugates Market: Distribution by Geographical Regions, 2023 and 2035
23.3.6.1. Antibody Drug Conjugates Market in North America, 2023-2035
23.3.6.1.1. Antibody Drug Conjugates Market in US, 2023-2035
23.3.6.1.2. Antibody Drug Conjugates Market in Canada, 2023-2035
23.3.6.2. Antibody Drug Conjugates Market in Europe, 2023-2035
23.3.6.2.1. Antibody Drug Conjugates Market in Germany, 2023-2035
23.3.6.2.2. Antibody Drug Conjugates Market in UK, 2023-2035
23.3.6.2.3. Antibody Drug Conjugates Market in France, 2023-2035
23.3.6.2.4. Antibody Drug Conjugates Market in Italy, 2023-2035
23.3.6.2.5. Antibody Drug Conjugates Market in Spain, 2023-2035
23.3.6.3. Antibody Drug Conjugates Market in Asia-Pacific, 2023-2035
23.3.6.3.1. Antibody Drug Conjugates Market in China, 2023-2035
23.3.6.3.2. Antibody Drug Conjugates Market in Australia, 2023-2035
23.3.6.3.3. Antibody Drug Conjugates Market in Japan, 2023-2035
23.4. Antibody Drug Conjugates Market: Product-wise Sales Forecast, 2023-2035
23.4.1. Adcetris
23.4.1.1. Sales Forecast (USD Billion)
23.4.1.2. Net Present Value (USD Billion)
23.4.1.3. Value Creation Analysis
23.4.2. Aidixi
23.4.2.1. Sales Forecast (USD Billion)
23.4.2.2. Net Present Value (USD Billion)
23.4.2.3. Value Creation Analysis
23.4.3. Besponsa
23.4.3.1. Sales Forecast (USD Billion)
23.4.3.2. Net Present Value (USD Billion)
23.4.3.3. Value Creation Analysis
23.4.4. Blenrep
23.4.4.1. Sales Forecast (USD Billion)
23.4.4.2. Net Present Value (USD Billion)
23.4.4.3. Value Creation Analysis
23.4.5. Elahere
23.4.5.1. Sales Forecast (USD Billion)
23.4.5.2. Net Present Value (USD Billion)
23.4.5.3. Value Creation Analysis
23.4.6. Enhertu
23.4.6.1. Sales Forecast (USD Billion)
23.4.6.2. Net Present Value (USD Billion)
23.4.6.3. Value Creation Analysis
23.4.7. Kadcyla
23.4.7.1. Sales Forecast (USD Billion)
23.4.7.2. Net Present Value (USD Billion)
23.4.7.3. Value Creation Analysis
23.4.8. Padcev
23.4.8.1. Sales Forecast (USD Billion)
23.4.8.2. Net Present Value (USD Billion)
23.4.8.3. Value Creation Analysis
23.4.9. Polivy
23.4.9.1. Sales Forecast (USD Billion)
23.4.9.2. Net Present Value (USD Billion)
23.4.9.3. Value Creation Analysis
23.4.10. Tivdak
23.4.10.1. Sales Forecast (USD Billion)
23.4.10.2. Net Present Value (USD Billion)
23.4.10.3. Value Creation Analysis
23.4.11. Trodelvy
23.4.11.1. Sales Forecast (USD Billion)
23.4.11.2. Net Present Value (USD Billion)
23.4.11.3. Value Creation Analysis
23.4.12. Zynlonta
23.4.12.1. Sales Forecast (USD Billion)
23.4.12.2. Net Present Value (USD Billion)
23.4.12.3. Value Creation Analysis
23.4.13. Datopotamab Deruxtecan
23.4.13.1. Sales Forecast (USD Billion)
23.4.13.2. Net Present Value (USD Billion)
23.4.13.3. Value Creation Analysis
23.4.14. Patritumab Deruxtecan
23.4.14.1. Sales Forecast (USD Billion)
23.4.14.2. Net Present Value (USD Billion)
23.4.14.3. Value Creation Analysis
23.4.15. SHR-A1811
23.4.15.1. Sales Forecast (USD Billion)
23.4.15.2. Net Present Value (USD Billion)
23.4.15.3. Value Creation Analysis
23.4.16. SKB264
23.4.16.1. Sales Forecast (USD Billion)
23.4.16.2. Net Present Value (USD Billion)
23.4.16.3. Value Creation Analysis
23.4.17. TAA013
23.4.17.1. Sales Forecast (USD Billion)
23.4.17.2. Net Present Value (USD Billion)
23.4.17.3. Value Creation Analysis
23.4.18. Telisotuzumab Vedotin
23.4.18.1. Sales Forecast (USD Billion)
23.4.18.2. Net Present Value (USD Billion)
23.4.18.3. Value Creation Analysis
23.4.19. Trastuzumab Duocarmazine
23.4.19.1. Sales Forecast (USD Billion)
23.4.19.2. Net Present Value (USD Billion)
23.4.19.3. Value Creation Analysis
23.4.20. Tusamitamab Ravtansine
23.4.20.1. Sales Forecast (USD Billion)
23.4.20.2. Net Present Value (USD Billion)
23.4.20.3. Value Creation Analysis
23.4.21. Upifitamab Rilsodotin
23.4.21.1. Sales Forecast (USD Billion)
23.4.21.2. Net Present Value (USD Billion)
23.4.21.3. Value Creation Analysis
24. EXECUTIVE INSIGHTS
24.1. Chapter Overview
24.2. Oxford Biotherapeutics
24.2.1. Company Snapshot
24.2.2. Interview Transcript: Christian Rohlff, Founder and Chief Executive Officer
24.3. Angiex
24.3.1. Company Snapshot
24.3.2. Interview Transcript: Paul Jaminet, Founder and Chief Operating Officer
24.4. Syndivia
24.4.1. Company Snapshot
24.4.2. Interview Transcript: Sasha Koniev, Co-Founder and Chief Executive Officer
24.5. BSP Pharmaceuticals
24.5.1. Company Snapshot
24.5.2. Interview Transcript: Aldo Braca, President and Chief Executive Officer and Giorgio Salciarini, Technical Business Development Senior Manager
24.6. PolyTherics (an Abzena company)
24.6.1. Company Snapshot
24.6.2. Interview Transcript: John Burt, Former Chief Executive Officer
24.7. CureMeta
24.7.1. Company Snapshot
24.7.2. Interview Transcript: Michael Schopperle, Founder and Chief Executive Officer
24.8. CytomX Therapeutics
24.8.1. Company Snapshot
24.8.2. Interview Transcript: Jeff Landau, Chief Business Officer and Head of Strategy
24.9. NBE-Therapeutics
24.9.1. Company Snapshot
24.9.2. Interview Transcript: Wouter Verhoeven, Former C